Sellas Life Sciences faces high risk in the Phase 3 REGAL AML trial for GPS. Click here to know why I rate the SLS stock a ...

FDA has previously agreed on the design of this 300-patient randomized, placebo-controlled confirmatory Phase 3 trial, and the 12-month primary endpoint of pain reduction as an approvable indication.

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®Phase 3 trial of ...

Eating too close to bedtime, especially a carb-heavy meal, can cause blood sugar levels to rise overnight. Try to eat earlier ...

Non-specific low back pain is a common condition with substantial socioeconomic implications. Pulsed electromagnetic field (PEMF) therapy is said to generate benefits in pain reduction and improvement ...

Poor Bexar County residents who received direct cash and coaching saved money, improved health and enrolled in education under pilot program.